Last update Aug. 19, 2021

Olodaterol Hydrochloride

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Long-acting beta-2 adrenergic agonist sympathomimetic with properties similar to salbutamol.
Indicated in the treatment of asthma.
Inhaled administration.

At the date of the last update, the authors did not find any published data on its excretion in breast milk.

Its very wide volume of distribution (Boehringer 2020 and 2019) and the fact that, after inhalation, it reaches very low or undetectable plasma concentrations, (Wang 2020, Ichinose 2015) making it very unlikely that significant amounts will pass into breast milk.
Its almost zero absorption and oral bioavailability (Boehringer 2020 and 2019) makes it difficult for it to pass to the infant plasma from ingested breast milk.

Experts and scientific societies consider the use of inhaled adrenergic agonists to be low risk during breastfeeding (Lactmed, Amir 2011, National Asthma Education 2004).

Alternatives

  • Formoterol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Salmeterol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Olodaterol Hydrochloride in other languages or writings:

Group

Olodaterol Hydrochloride belongs to this group or family:

Tradenames

Main tradenames from several countries containing Olodaterol Hydrochloride in its composition:

  • Inspiolto™. Contains other elements than Olodaterol Hydrochloride in its composition
  • Spiolto™. Contains other elements than Olodaterol Hydrochloride in its composition
  • Spiolto (Спиолто)™. Contains other elements than Olodaterol Hydrochloride in its composition
  • Stiolto™. Contains other elements than Olodaterol Hydrochloride in its composition
  • Striverdi
  • Striverdi (Стриверди)
  • Yanimo™. Contains other elements than Olodaterol Hydrochloride in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 1 (Inhal: 30) %
Molecular weight 423 daltons
Protein Binding 60 %
VD 15.9 l/Kg
pKa 9.22 -
Tmax 0.2 - 0.3 hours
22 - 45 hours

References

  1. LactMed. Drugs and Lactation Database (LactMed). Internet. Bethesda (MD): National Library of Medicine (US); 2006-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501922/ 2006 - Consulted on March 15, 2022 Full text (link to original source)
  2. Middleton PG, Gade EJ, Aguilera C, MacKillop L, Button BM, Coleman C, Johnson B, Albrechtsen C, Edenborough F, Rigau D, Gibson PG, Backer V. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. Eur Respir J. 2020 Feb 6;55(2). pii: 1901208. Abstract Full text (link to original source) Full text (in our servers)
  3. Boehringer. Olodaterol. Ficha técnica. 2020 Full text (in our servers)
  4. Wang Z, Tadayasu Y, Hu N, Shu S, Hu C, Luo Z. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD. Pulm Pharmacol Ther. 2020 Aug;63:101944. Abstract
  5. Boheringer. Olodaterol. Drug Summary. 2019 Full text (in our servers)
  6. Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, Kunz C, Fukuchi Y. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Aug 20;10:1673-83. Abstract
  7. Amir LH, Pirotta MV, Raval M. Breastfeeding--evidence based guidelines for the use of medicines. Aust Fam Physician. 2011 Sep;40(9):684-90. Review. Abstract Full text (link to original source) Full text (in our servers)
  8. National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. 2004;1-57. None 2004 Full text (link to original source) Full text (in our servers)

Total visits

3,229

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM